NASDAQ:OBSV

ObsEva Stock Forecast, Price & News

$4.14

-0.36 (-8.00 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.03

Now: $4.14▼

$4.25

50-Day Range

$1.93

MA: $2.37▼

$4.50

52-Week Range

$1.63

Now: $4.14▼

$6.30

Volume4.04 million shs

Average Volume16.74 million shs

Market Capitalization$198.72 million

P/E RatioN/A

Dividend YieldN/A

Beta0.99

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

MarketRank^™

Overall MarketRank^™

1.39 out of 5 stars

Medical Sector

551st out of 1,926 stocks

Pharmaceutical Preparations Industry

279th out of 773 stocks

3.2 Analyst's Opinion

Consensus Rating
ObsEva has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $11.80, ObsEva has a forecasted upside of 185.0% from its current price of $4.14.
Amount of Analyst Coverage
ObsEva has only been the subject of 4 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
ObsEva has received 302 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ObsEva has received 344 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ObsEva has received 53.25% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ObsEva and other stocks. Vote “Outperform” if you believe OBSV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ObsEva does not currently pay a dividend.
Dividend Growth
ObsEva does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ObsEva insiders have not sold or bought any company stock.
Percentage Held by Institutions
52.74% of the stock of ObsEva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ObsEva are expected to grow in the coming year, from ($1.78) to ($1.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ObsEva is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ObsEva is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ObsEva has a P/B Ratio of 4.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:OBSV

Previous Symbol

CUSIPN/A

CIK1685316

Webwww.obseva.com

Phone41-22-552-3840

Employees53

Debt

Debt-to-Equity Ratio1.14

Current Ratio2.06

Quick Ratio2.06

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.01 per share

Price / Book4.10

Profitability

EPS (Most Recent Fiscal Year)($2.49)

Net Income$-108,790,000.00

Net MarginsN/A

Return on Equity-256.23%

Return on Assets-93.21%

Miscellaneous

Outstanding Shares47,999,000

Market Cap$198.72 million

Next Earnings Date3/4/2021 (Estimated)

OptionableNot Optionable

$4.14

-0.36 (-8.00 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.

ObsEva (NASDAQ:OBSV) Frequently Asked Questions

How has ObsEva's stock been impacted by COVID-19?

ObsEva's stock was trading at $2.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OBSV stock has increased by 61.1% and is now trading at $4.14.
View which stocks have been most impacted by COVID-19.

Is ObsEva a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ObsEva stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OBSV, but not buy additional shares or sell existing shares.
View analyst ratings for ObsEva or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than ObsEva?

Wall Street analysts have given ObsEva a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ObsEva wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as ObsEva's CEO?

1,448 employees have rated ObsEva CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among ObsEva's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is ObsEva's next earnings date?

ObsEva is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for ObsEva.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) issued its earnings results on Thursday, November, 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.15.
View ObsEva's earnings history.

What price target have analysts set for OBSV?

5 equities research analysts have issued 1-year price objectives for ObsEva's shares. Their forecasts range from $4.00 to $28.00. On average, they anticipate ObsEva's stock price to reach $11.80 in the next year. This suggests a possible upside of 185.0% from the stock's current price.
View analysts' price targets for ObsEva or view Wall Street analyst' top-rated stocks.

Who are some of ObsEva's key competitors?

Some companies that are related to ObsEva include MannKind (MNKD), Merus (MRUS), Aclaris Therapeutics (ACRS), Avid Bioservices (CDMO), ZIOPHARM Oncology (ZIOP), Gossamer Bio (GOSS), Calliditas Therapeutics AB (publ) (CALT), Odonate Therapeutics (ODT), VBI Vaccines (VBIV), Inventiva (IVA), Esperion Therapeutics (ESPR), Foghorn Therapeutics (FHTX), Syros Pharmaceuticals (SYRS), AnaptysBio (ANAB) and Zafgen (ZFGN).
View all of OBSV's competitors.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

Who are ObsEva's key executives?

ObsEva's management team includes the following people:

Dr. Ernest Loumaye, Co-Founder & Director (Age 69, Pay $944k)
Mr. Brian O'Callaghan, Chief Exec. Officer (Age 52)
Mr. David Renas, Chief Financial Officer
Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 56)
Mr. Fabien Lefebvre de Ladonchamps, Chief Admin. Officer (Age 42)
Mr. Mario Vincent Corso, Sr. Director of Investor Relations
Ms. Delphine Renaud, Personal Assistant to the CSO and Head of R&D
Mr. Wim Souverijns, Chief Commercial Officer (Age 50)
Dr. Elizabeth Ijeoma Onyemelukwe Garner, Chief Medical Officer (Age 53)

When did ObsEva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

How do I buy shares of ObsEva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $4.14.

How big of a company is ObsEva?

ObsEva has a market capitalization of $198.72 million. The company earns $-108,790,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. ObsEva employs 53 workers across the globe.

What is ObsEva's official website?

The official website for ObsEva is www.obseva.com.

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here